Clinical trials: Renal Transplant Recipients
End Stage Renal Disease
Trial of Adoptive Immunotherapy With TRACT to Prevent Rejection in Living Donor Kidney Transplant Recipients
Regulatory CD4+CD25+ T cells (Treg) derived from the thymus and/or peripheral tissues have been demonstrated to broadly control T cell reactivity (14).
- Trial name
- TRACT (NCT02145325)
- Testing
- Expanded Tregs
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Northwestern University
Renal Failure
Induction of Donor Specific Tolerance in Recipients of Live Donor Kidney Allografts by Donor Stem Cell Infusion
The goal of this research study is to establish chimerism and avoid graft-versus-host disease in patients with kidney failure allowing a reduction or cessation of immune-suppressive therapy.
- Trial name
- NCT00498160
- Testing
- Enriched Hematopoietic Stem Cell Infusion
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- Talaris Therapeutics Inc.
Renal Transplant
CellCept® Dose Adjustment Versus Fixed Dose (Standard Care) in Renal Transplant Recipients
In order to avoid renal transplant rejection, the immune system should be suppressed. After the renal transplant subjects are treated with a combination of two to four different types of immunosuppressive drugs.
- Trial name
- MMF (NCT00737659)
- Testing
- Mycophenolate mofetil (CellCept® )
- Where
- 2 sites in Israel
- Volunteers
- 138 people
- Sponsor
- Rabin Medical Center
HIV Infections, Kidney Diseases
Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients
Maraviroc (MVC) is a type of HIV medicine called a CCR5 inhibitor. This study will evaluate the safety and tolerability of MVC in HIV-infected adults receiving a kidney transplant.
- Trial name
- NCT02741323
- Testing
- Maraviroc
- Where
- 10 sites in United States
- Volunteers
- 97 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Epstein-Barr Virus Infections
EBV Infection as a Risk Factor for PTLD in Pediatric and Adult Renal Transplant Recipients
Question: In which stage of an EBV-infection is a selective reduction of immunosuppressive medication reasonable to minimize the risk for PTLD, without putting the transplant recipient at risk of acute rejection episodes due to…
- Trial name
- NCT00963248
- Where
- Germany
- Volunteers
- 106 people
- Sponsor
- Klinik für Kinder- und Jugendmedizin
Kidney Failure
RUCONEST® as a Therapeutic Strategy to Reduce the Incidence of Delayed Graft Function
An unmet medical need exists for therapeutic regimens in transplantation that allow immediate postoperative graft function, thereby improving graft survival.
- Trial name
- NCT03791476
- Testing
- rhC1INH, Saline Solution
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Wisconsin, Madison
Kidney Transplant
Clinical Outcome of Delayed or Standard Prograf Together With Induction Therapy Followed by Conversion to Advagraf in Donation After Cardiac (or Circulatory) Death (DCD) Kidney Transplant Recipients
The purpose of this study is to confirm non-inferiority of delayed Prograf treatment to standard Prograf treatment in the incidence of delayed graft function (DGF) within 1 week between the 2 immunosuppressive (IS) treatment…
- Trial name
- NCT03644485
- Testing
- Tacrolimus immediate-release formulation, Tacrolimus prolonged-release formulation, Induction therapy
- Where
- 14 sites in China
- Volunteers
- 284 people
- Sponsor
- Astellas Pharma China, Inc.
Tacrolimus-associated Abnormal Glucose Metabolism in Kidney and Liver Transplant Recipients
Safety and Efficacy of Converting Maintenance Kidney and Liver Transplant Recipients With Abnormal Glucose Metabolism From Tacrolimus to Cyclosporine Micro-emulsion
New onset diabetes mellitus (NODM) post- transplantation decreases patient and graft survival. Some immunosuppressive agents are associated with a higher incidence of NODM.
- Trial name
- NCT00150085
- Testing
- cyclosporine micro-emulsion
- Volunteers
- 50 people
- Sponsor
- Novartis
Renal Transplant Rejection
Calcineurin Activity in Renal Recipients
The purpose is to define if calcineurin activity is a better biological parameter than blood concentration for the therapeutic tacrolimus monitoring.
- Trial name
- NCT01413685
- Testing
- Pharmacokinetics/dynamics
- Where
- France
- Volunteers
- 23 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Renal Transplantation
Study Evaluating Sirolimus and Cyclosporine in Kidney Transplant Recipients
To assess equivalence in the rates of functional graft survival at 12 months after transplantation in patients receiving continuous therapy with cyclosporine (CsA, Sandimmune, Neoral) and sirolimus versus induction with CsA and…
- Trial name
- NCT00428064
- Testing
- Sirolimus, cyclosporine
- Volunteers
- 408 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Disorder Related to Renal Transplantation, Hypercholesterolemia
The Rosuvastatin In TrAnsplant Recipients Study
Renal transplant recipients need life long immunosuppression and one of the new drugs is everolimus. Everolimus is a potent immunosuppressive drug and one of the main side-effects are increased blood cholesterol levels.
- Trial name
- RITA (NCT01524601)
- Testing
- Rosuvastatin
- Where
- Norway
- Volunteers
- 20 people
- Sponsor
- University of Oslo School of Pharmacy
Renal Transplantation
Muscle Oxygenation, Functional Capacity and Frailty in Kidney Transplant Recipients with and Without Inspiratory Muscle Weakness
The aim of this study was to compare respiratory function, muscle oxygenation, functional capacity, peripheral muscle strength, body composition, and frailty in kidney transplant recipients with and without inspiratory muscle…
- Trial name
- NCT06706492
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Hacettepe University
Heart Transplantation, Acute Renal Failure
Metabolic Pattern of Cyclosporine A and Acute Renal Failure
Following heart transplantation many patients develop acute renal failure in the early posttransplant phase and some are in need of renal replacement therapy for shorter or longer time.
- Trial name
- NCT00264355
- Testing
- cyclosporine A
- Where
- Norway
- Volunteers
- 30 people
- Sponsor
- University of Oslo School of Pharmacy
Cytomegalovirus Infections, CMV
Cytomegalovirus Risk in Seropositive Kidney Transplant Recipients Stratified by Quantiferon-CMV
To evaluate the Quantiferon-CMV test ability to predict occurrence of cytomegalovirus (CMV) disease o treated infection after kidney transplantation.
- Conditions
- Cytomegalovirus Infections, CMV, Kidney Transplant Infection
- Trial name
- NCT03858907
- Where
- Brazil
- Volunteers
- 180 people
- Sponsor
- University of Sao Paulo General Hospital
Transplant Recipient (Kidney)
Immune Monitoring-Guided Individualized Tacrolimus Therapy in Renal Transplant Recipients: An Observational Study and PK/PD Modeling
This study aims to resolve the clinical limitation that therapeutic drug monitoring (TDM) alone cannot accurately reflect the net immune status after kidney transplantation.
- Trial name
- NCT07815938
- Testing
- No interventional treatment, only observational data collection without clinical drug adjustment
- Volunteers
- 50 people
- Sponsor
- Zhongnan Hospital
Latent Tuberculosis Infection
Interferon Gamma Release Assays (IGRA) Testing Versus Tuberculin Skin Test in Renal Transplant Recipients
Interferon gamma release assays (IGRA) have been shown to be more specific and sensitive for the detection of tuberculosis (latent or active infection) than the tuberculin skin test (TST) in immunocompetent individuals.
- Trial name
- NCT01608685
- Where
- Switzerland
- Volunteers
- 205 people
- Sponsor
- Ligue Pulmonaire Genevoise
Human Influenza
Clinical Trial for the Evaluation of Three Regimens of Influenza Vaccination in Kidney Transplant Recipients
This will be an open label, parallel, randomized clinical trial that will evaluate the immunogenicity and safety of the trivalent influenza vaccine (inactivated and fragmented) produced by Instituto Butantan among adult kidney…
- Trial name
- NCT02104869
- Testing
- Trivalent influenza vaccine (inactivated and fragmented).
- Where
- Brazil
- Volunteers
- 195 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
Kidney; Complications, Allograft
Evaluate Efficacy Study of Combination Therapy of Everolimus and Low Dose Tacrolimus in Renal Allograft Recipients
To evaluate prevention effect of combination therapy of Everolimus and low-dose Tacrolimus in comparison with standard-dose Tacrolimus therapy with Mycophenolic acid on the New Onset Diabetes Mellitus after transplantation in the…
- Trial name
- PROTECT (NCT02036554)
- Testing
- Everolimus, Tacrolimus, Mycophenolic acid
- Where
- South Korea
- Volunteers
- 234 people
- Sponsor
- Seoul St. Mary's Hospital
Kidney Transplantation
Certican (Everolimus) for Recipients of Kidney From HLA-identical Living Donors
Recipients from living donors kidneys HLA-identical were lower risk for acute rejection, graft loss or death. There is no clear definition of what is ideal immunosuppressive regimen for this population.
- Trial name
- NCT01653041
- Testing
- Everolimus
- Where
- Brazil
- Volunteers
- 47 people
- Sponsor
- Hospital do Rim e Hipertensão
Change of Transit or Circulation, Effects of Immunosuppressant Therapy
Gastrointestinal Transit and Motility in Renal Transplant Recipients
Gastrointestinal (GI) complications after renal transplantation are commonly reported as side effects of immunosuppressive agents. Despite this, motility disorders have been scantily studied.
- Trial name
- NCT01777204
- Where
- Brazil
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Universidade Estadual de Ciências da Saúde de Alagoas
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.